Cognition Therapeutics, Inc. (CGTX) Earnings
Cognition Therapeutics, Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $-0.06. CGTX has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise +26.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.06 | $-0.05 | +16.7% | — | — |
| Mar 26, 2026 | $-0.06 | $-0.02 | +66.7% | — | — |
| Nov 6, 2025 | $-0.07 | $-0.06 | +14.3% | — | — |
| Aug 7, 2025 | $-0.12 | $-0.11 | +8.3% | — | — |
| May 7, 2025 | $-0.12 | $-0.14 | -16.7% | — | — |
| Mar 20, 2025 | $-0.16 | $-0.17 | -6.3% | — | — |
| Aug 8, 2024 | $-0.22 | $-0.18 | +18.2% | — | — |
| Nov 2, 2023 | $-0.31 | $-0.22 | +29.0% | — | — |
| May 4, 2023 | $-0.17 | $-0.21 | -23.5% | — | — |
| Mar 23, 2023 | $-0.49 | $-0.20 | +59.2% | — | — |
| Nov 14, 2022 | $-0.55 | $-0.29 | +47.3% | — | — |
| Nov 17, 2021 | $-0.57 | $-8.12 | -1324.6% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2025 · March 26, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Cognition's primary focus is on developing Xervimicine (Zurimacine/CT1812) for neurodegenerative diseases. Prioritized development of zirvimicine for DLB psychosis based on phase two study results. Phase two shimmer study in DLB showed impact on symptom domains including psychosis. Discussed with FDA and plan to meet with Division of Psychiatry. Completed enrollment in 545-patient START trial in early Alzheimer's disease. EAP program for zirvimicine had strong interest. SHINE study in mild to moderate Alzheimer's disease showed 38% reduction in cognitive decline. R&D expenses decreased in 2025, G&A expenses also decreased. Cash, cash equivalents, and restricted cash equivalents as of Dec 31, 2025 were ~$37M, with sufficient cash to fund operations through Q2 2027.
Analyst Q&A
Q: Do you guys plan to seek a partner for further exploration with derma medicine, particularly in ocular conditions? If so, when?
A: Right now, our priority is on developing Zervimicine for DLB. And so we're not looking at an ophthalmology program at the moment.
Q: Walk us through what you see as the big regulatory path forward for the DLB program. Should we expect your next trial to be registrational or go to phase three directly? And current thinkings on DLB trial size, duration, primary endpoint?
A: Intent is to develop for DLB psychosis label like Nuplasid and Rixalti. Have not completed FDA meetings to comment on outcome measure. Intent is to move expeditiously through registrational trials.
Q: State of the art in terms of the hypothesis behind Zerva-Messing's mechanism of action on psychosis? Any similar anecdotes from patients in SHINE study?
A: Believe it's interrupting basic pathophysiology by blocking interaction of alpha-synuclein with receptors. Don't have too much detail on anecdotes from SHINE study.
Q: In proposed DLB psychosis trial, what would the time point be to primary endpoint on psychosis? Do you expect secondary endpoints involving cognition?
A: Have not announced exactly study details. Will be topic of discussion with FDA. Will have secondary measures including cognition and others. Focus on psychosis now for smaller, faster trials.
Q: How does the effect of surveillance on behavioral domains in DLB affect thinking about pursuing behavioral domains in Alzheimer's disease?
A: Want to see results of START trial. Hope it builds on SHINE results, particularly in patients with low PTAL. Prioritize DLB study first, then see results of START for AD.
Q: How does the effect of surveillance on behavioral domains in DLB affect thinking about pursuing behavioral domains in Alzheimer's disease?
A: Want to see results of START trial. Hope it builds on SHINE results, particularly in patients with low PTAL. Prioritize DLB study first, then see results of START for AD.
Q: Where are you in meetings with EMA for DLB? Do you anticipate trial including sites in US and Europe?
A: Haven't announced exactly where trial will be. Once agreement with FDA, will seek alignment with EMA. Premature to talk about plans.
Q: Which existing approved CNS medications might the medicine exhibit synergy? Plan to explore synergies clinically?
A: Most studies done on CNS standard of care background medications. In DLB trial, 80-85% on acetylcholine esterase inhibitors. In START trial in early AD, allowed people on stable maintenance course of immunotherapies. Will collect data on combination benefits.